Rowing and cycling exercise and inflammation in newly diagnosed type 2 diabetes
Compares rowing and cycling exercise plans in adults recently diagnosed with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Rowing and Cycling Reduce Inflammation in Early-Stage Type 2 Diabetes
Key facts
- Where
- Putian, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07769840, who can take part
Where in China
- The Ethics Committee of Putian 95 HospitalPutian, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The 95th Hospital of Putian，Putian, Fujian, China
- Trial code
- NCT07769840
- Record updated
- 18 August 2026
- Original description
This multicenter randomized controlled trial evaluates the short-term (7-day) effects of different rowing-cycling exercise regimens on postprandial glycemic excursions in newly diagnosed type 2 diabetes patients (aged 18-60 years, diagnosis ≤12 months, drug-naïve). A total of 120 participants will be randomized into five groups: control, moderate-intensity continuous cycling, high-intensity interval rowing, and standard combined exercise (rowing + cycling, 50 min). The primary outcome is inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-1ra, IL-10, hs-CRP), body Composition and functional Indicators. Secondary outcomes include change in continuous glucose monitoring-derived glycemic variability (CONGA), and time-in-range. Mixed-effects models will quantify dose-response relationships and identify key effect modifiers (e.g., age). This study aims to establish an evidence-based precision exercise prescription for early-stage type 2 diabetes management.Read full original descriptionShow less
Effects of Different Modes of Rowing Combined With Cycling Exercise on Inflammatory Markers in Newly Diagnosed Type 2 Diabetes Patients
This multicenter randomized controlled trial evaluates the short-term (7-day) effects of different rowing-cycling exercise regimens on postprandial glycemic excursions in newly diagnosed type 2 diabetes patients (aged 18-60 years, diagnosis ≤12 months, drug-naïve). A total of 120 participants will be randomized into five groups: control, moderate-intensity continuous cycling, high-intensity interval rowing, and standard combined exercise (rowing + cycling, 50 min). The primary outcome is inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-1ra, IL-10, hs-CRP), body Composition and functional Indicators. Secondary outcomes include change in continuous glucose monitoring-derived glycemic variability (CONGA), and time-in-range. Mixed-effects models will quantify dose-response relationships and identify key effect modifiers (e.g., age). This study aims to establish an evidence-based precision exercise prescription for early-stage type 2 diabetes management.
Inclusion: Age between 18-60 years, no gender limited; Meeting the WHO 1999 diagnostic criteria for T2DM, with a diagnosis time ≤12 months; Not having received hypoglycemic drug treatment (or only lifestyle intervention, and stopped medication ≥4 weeks before enrollment); Fasting blood glucose 7.0-13.9 mmol/L, glycated hemoglobin (HbA1c) 6.5%-10.0%; No regular exercise in the past 3 months (less than 2 times per week of moderate or higher intensity exercise, each <30 minutes); Voluntarily signing the informed consent form.
Exclusion: Type 1 diabetes, gestational diabetes, or other special types of diabetes; Severe cardiovascular or cerebrovascular diseases (NYHA heart function ≥III, recent myocardial infarction or unstable angina); Uncontrolled hypertension (resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg); Mental illness or cognitive impairment that prevents compliance with the study; Stress events such as infection, trauma, or surgery in the past month; Musculoskeletal diseases of the upper or lower limbs that affect rowing machine or bicycle exercise; Severe liver or kidney dysfunction (ALT/AST ≥3 times the upper limit of normal, or eGFR<60 mL/min/1.73m²); Severe diabetic complications (such as proliferative retinopathy, severe neuropathy, diabetic foot); Pregnant or breastfeeding women; Participation in other interventional clinical studies.